Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 05, 2016; 86 (16 Supplement) April 18, 2016

A 24-Week, Phase III, Double-Blind, Parallel-Group Study of Edaravone (MCI-186) for Treatment of Amyotrophic Lateral Sclerosis (ALS) (P3.189)

Masahiko Tanaka, Takeshi Sakata, Joseph Palumbo, Makoto Akimoto
First published April 4, 2016,
Masahiko Tanaka
1Mitsubishi Tanabe Pharma Corporation Tokyo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeshi Sakata
1Mitsubishi Tanabe Pharma Corporation Tokyo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Palumbo
2Mitsubishi Tanabe Pharma Development America Inc Jersey City NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Makoto Akimoto
1Mitsubishi Tanabe Pharma Corporation Tokyo Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
A 24-Week, Phase III, Double-Blind, Parallel-Group Study of Edaravone (MCI-186) for Treatment of Amyotrophic Lateral Sclerosis (ALS) (P3.189)
Masahiko Tanaka, Takeshi Sakata, Joseph Palumbo, Makoto Akimoto
Neurology Apr 2016, 86 (16 Supplement) P3.189;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective:To investigate the efficacy and safety of edaravone versus placebo in a more narrowly defined population of patients (Edaravone MCI-186-J19/NCT01492686), intended to replicate the findings of a previous post hoc analysis. Background:The efficacy of edaravone was previously evaluated in a randomized placebo controlled phase III study (Abe K et al. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15: 610-7). This study did not demonstrate efficacy versus placebo of edaravone as an investigative treatment for ALS, but hypothesis-driven post hoc analyses suggested an opportunity to demonstrate efficacy in a more narrowly defined patient population. Design/Methods: 137 patients were randomized 1:1 to receive edaravone or placebo following a 12-week pre-observation period. Selection criteria included: Definite or Probable ALS (El Escorial/revised Airlie House); Japan ALS severity classification grade<3; scoring≥2 points on each single ALSFRS-R item at screening; [percnt] forced vital capacity≥80[percnt]; and ALS duration≤2 years. Treatment consisted of 6 cycles of 60-mg edaravone/matching placebo treatment. Primary efficacy endpoint was change in ALS Functional Rating Scale-Revised (ALSFRS-R) score at week 24. Secondary endpoints included change in ALS Assessment Questionnaire (ALSAQ40) scores. Safety endpoints included adverse events (AEs) and laboratory tests. Results:Mean change (±SE) in ALSFRS-R score was -7.50±0.66 (placebo) and -5.01±0.64 (edaravone): a between group difference of 2.49±0.76 (P=0.001). Between group difference for ALSAQ40 was -8.79±4.03 (P=0.031). Both groups showed similar AE incidence (84.1[percnt] edaravone, 83.8[percnt] placebo). Incidence of serious AEs was 15.9[percnt] (edaravone) and 23.5[percnt] (placebo). The most common AEs were contusion, and dysphagia (16[percnt] and 13[percnt] of patients, respectively). Incidence of adverse drug reactions (ADRs) was 2.9[percnt] (edaravone) and 7.4[percnt] (placebo). There were no serious ADRs and no AEs that lead to death. Conclusion:Edaravone treated ALS patients meeting the protocol inclusion criteria had less functional loss at 6 months, and had less quality of life deterioration compared to those receiving standard of care.

Disclosure: Dr. Tanaka has received personal compensation for activities with Mitsubishi Tanabe Pharma Corporation. Dr. Sakata has received personal compensation for activities with the Mitsubishi Tanabe Pharmaceutical Corporation. Dr. Palumbo has received personal compensation for activities with Mitsubishi Tanabe Pharma Corporation. Dr. Akimoto has received personal compensation for activities with Mitsubishi Tanabe Pharma Corporation.

Monday, April 18 2016, 8:30 am-7:00 pm

  • Copyright © 2016 by AAN Enterprises, Inc.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Dr. Nicole Sur and Dr. Mausaminben Hathidara

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise